Managing infective endocarditis in the elderly: new issues for an old disease

Emmanuel Forestier, Thibaut Fraisse, Claire Roubaud-Baudron, Christine Selton-Suty, Leonardo Pagani, Emmanuel Forestier, Thibaut Fraisse, Claire Roubaud-Baudron, Christine Selton-Suty, Leonardo Pagani

Abstract

The incidence of infective endocarditis (IE) rises in industrialized countries. Older people are more affected by this severe disease, notably because of the increasing number of invasive procedures and intracardiac devices implanted in these patients. Peculiar clinical and echocardiographic features, microorganisms involved, and prognosis of IE in elderly have been underlined in several studies. Additionally, elderly population appears quite heterogeneous, from healthy people without past medical history to patients with multiple diseases or who are even bedridden. However, the management of IE in this population has been poorly explored, and international guidelines do not recommend adapting the therapeutic strategy to the patient's functional status and comorbidities. Yet, if IE should be treated according to current recommendations in the healthiest patients, concerns may rise for older patients who suffer from several chronic diseases, especially renal failure, and are on polypharmacy. Treating frailest patients with high-dose intravenous antibiotics during a prolonged hospital stay as recommended for younger patients could also expose them to functional decline and toxic effect. Likewise, the place of surgery according to the aging characteristics of each patient is unclear. The aim of this article is to review the recent data on epidemiology of IE and its peculiarities in the elderly. Then, its management and various therapeutic approaches that can be considered according to and beyond guidelines depending on patient comorbidities and frailty are discussed.

Keywords: antibiotic therapy; cardiac surgery; elderly; frailty; infective endocarditis.

References

    1. Selton-Suty C, Célard M, Le Moing V, et al. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis. 2012;54(9):1230–1239.
    1. Slipczuk L, Codolosa JN, Davila CD, et al. Infective endocarditis epidemiology over five decades: a systematic review. PloS One. 2013;8(12):e82665.
    1. Ramírez-Duque N, García-Cabrera E, Ivanova-Georgieva R, et al. Surgical treatment for infective endocarditis in elderly patients. J Infect. 2011;63(2):131–138.
    1. Lopez J, Revilla A, Vilacosta I, et al. Age-dependent profile of left-sided infective endocarditis: a 3-center experience. Circulation. 2010;121(7):892–897.
    1. Remadi JP, Nadji G, Goissen T, Zomvuama NA, Sorel C, Tribouilloy C. Infective endocarditis in elderly patients: clinical characteristics and outcome. Eur J Cardiothorac Surg. 2009;35(1):123–129.
    1. Durante-Mangoni E, Bradley S, Selton-Suty C, et al. Current features of infective endocarditis in elderly patients: results of the International Collaboration on Endocarditis Prospective Cohort Study. Arch Intern Med. 2008;168(19):2095–2103.
    1. High KP, Bradley S, Loeb M, Palmer R, Quagliarello V, Yoshikawa T. A new paradigm for clinical investigation of infectious syndromes in older adults: assessment of functional status as a risk factor and outcome measure. Clin Infect Dis. 2005;40(1):114–122.
    1. Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation. 2010;121(3):458–477.
    1. Gould FK, Denning DW, Elliott TSJ, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2012;67(2):269–289.
    1. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM) Eur Heart J. 2015;36(44):3075–3128.
    1. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435–1486.
    1. Delahaye F, Goulet V, Lacassin F, et al. Characteristics of infective endocarditis in France in 1991. A 1-year survey. Eur Heart J. 1995;16(3):394–401.
    1. Hoen B, Duval X. Infective endocarditis. N Engl J Med. 2013;369(8):785.
    1. Ferreiros E, Nacinovich F, Casabé JH, et al. Epidemiologic, clinical, and microbiologic profile of infective endocarditis in Argentina: a national survey. The Endocarditis Infecciosa en la República Argentina-2 (EIRA-2) Study. Am Heart J. 2006;151(2):545–552.
    1. Benito N, Miró JM, de Lazzari E, et al. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med. 2009;150(9):586–594.
    1. Cabell CH, Jollis JG, Peterson GE, et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med. 2002;162(1):90–94.
    1. Dhawan VK. Infective endocarditis in elderly patients. Curr Infect Dis Rep. 2003;5(4):285–292.
    1. Di Salvo G, Thuny F, Rosenberg V, et al. Endocarditis in the elderly: clinical, echocardiographic, and prognostic features. Eur Heart J. 2003;24(17):1576–1583.
    1. Gregoratos G. Infective endocarditis in the elderly: diagnosis and management. Am J Geriatr Cardiol. 2003;12(3):183–189.
    1. Selton-Suty C, Hoen B, Grentzinger A, et al. Clinical and bacteriological characteristics of infective endocarditis in the elderly. Heart Br Card Soc. 1997;77(3):260–263.
    1. Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H, et al. Infective endocarditis after transcatheter aortic valve implantation: results from a large multicenter registry. Circulation. 2015;131(18):1566–1574.
    1. Pericas JM, Llopis J, Cervera C, et al. Infective endocarditis in patients with an implanted transcatheter aortic valve: clinical characteristics and outcome of a new entity. J Infect. 2015;70(6):565–576.
    1. Verhagen DWM, Hermanides J, Korevaar JC, et al. Health-related quality of life and posttraumatic stress disorder among survivors of left-sided native valve endocarditis. Clin Infect Dis. 2009;48(11):1559–1565.
    1. McMillan GJ, Hubbard RE. Frailty in older inpatients: what physicians need to know. QJM. 2012;105(11):1059–1065.
    1. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J. 2012;33(19):2403–2418.
    1. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol. 2001;56(3):M146–M156.
    1. Rodriguez Villarreal I, Ortega O, Hinostroza J, et al. Geriatric assessment for therapeutic decision-making regarding renal replacement in elderly patients with advanced chronic kidney disease. Nephron Clin Pract. 2014;128(1–2):73–78.
    1. Faulkner CM, Cox HL, Williamson JC. Unique aspects of antimicrobial use in older adults. Clin Infect Dis. 2005;40(7):997–1004.
    1. Fraisse T, Gras Aygon C, Paccalin M, et al. Aminoglycosides use in patients over 75 years old. Age Ageing. 2014;43(5):676–681.
    1. Sandoe JA, Patel PA, Baig MW, West R. What is the effect of penicillin dosing interval on outcomes in streptococcal infective endocarditis? J Antimicrob Chemother. 2013;68(11):2660–2663.
    1. Hughes DW, Frei CR, Maxwell PR, et al. Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53(5):2014–2019.
    1. Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(1):17–24.
    1. Lee C-H, Tsai C-Y, Li C-C, Chien C-C, Liu J-W. Teicoplanin therapy for MRSA bacteraemia: a retrospective study emphasizing the importance of maintenance dosing in improving clinical outcomes. J Antimicrob Chemother. 2015;70(1):257–263.
    1. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–665.
    1. Konychev A, Heep M, Moritz RKC, et al. Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: an open-label, multicentre, randomized phase IIIb trial. Drugs Aging. 2013;30(10):829–836.
    1. Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev. 2014;1:CD003344.
    1. Fernández-Hidalgo N, Almirante B, Gavaldà J, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis. 2013;56(9):1261–1268.
    1. Pericas JM, Cervera C, del Rio A, et al. Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone. Clin Microbiol Infect. 2014;20(12):O1075–O1083.
    1. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650–655.
    1. Murry KR, McKinnon PS, Mitrzyk B, Rybak MJ. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy. 1999;19(11):1252–1260.
    1. Raveh D, Kopyt M, Hite Y, Rudensky B, Sonnenblick M, Yinnon AM. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. QJM. 2002;95(5):291–297.
    1. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007;45(6):753–760.
    1. Foltz F, Ducher M, Rougier F, et al. Efficacy and toxicity of aminoglycoside therapy in the elderly: combined effect of both once-daily regimen and therapeutic drug monitoring. Pathol Biol (Paris) 2002;50(4):227–232.
    1. Amodeo MR, Clulow T, Lainchbury J, et al. Outpatient intravenous treatment for infective endocarditis: safety, effectiveness and one-year outcomes. J Infect. 2009;59(6):387–393.
    1. Cervera C, del Río A, García L, et al. Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study. Enfermedades Infecc Microbiol Clínica. 2011;29(8):587–592.
    1. Partridge DG, O’Brien E, Chapman ALN. Outpatient parenteral antibiotic therapy for infective endocarditis: a review of 4 years’ experience at a UK centre. Postgrad Med J. 2012;88(1041):377–381.
    1. Duncan CJA, Barr DA, Ho A, Sharp E, Semple L, Seaton RA. Risk factors for failure of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis. J Antimicrob Chemother. 2013;68(7):1650–1654.
    1. Lacroix A, Revest M, Patrat-Delon S, et al. Outpatient parenteral antimicrobial therapy for infective endocarditis: a cost-effective strategy. Med Mal Infect. 2014;44(7):327–330.
    1. Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. Clin Infect Dis. 2004;38(12):1651–1671.
    1. Dardaine-Giraud V, Lamandé M, Constans T. Hypodermoclysis: benefits and indications in geriatrics. Rev Med Int. 2005;26(8):643–650.
    1. Frisoli Junior A, de Paula AP, Feldman D, Nasri F. Subcutaneous hydration by hypodermoclysis. A practical and low cost treatment for elderly patients. Drugs Aging. 2000;16(4):313–319.
    1. Remington R, Hultman T. Hypodermoclysis to treat dehydration: a review of the evidence. J Am Geriatr Soc. 2007;55(12):2051–2055.
    1. Forestier E, Paccalin M, Roubaud-Baudron C, Fraisse T, Gavazzi G, Gaillat J. Subcutaneously administered antibiotics: a national survey of current practice from the French infectious diseases (SPILF) and geriatric medicine (SFGG) society networks. Clin Microbiol Infect. 2015;21(4):370.
    1. Borner K, Lode H, Hampel B, Pfeuffer M, Koeppe P. Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. Chemotherapy. 1985;31(4):237–245.
    1. Bricaire F, Castaing JL, Pocidalo JJ, Vilde JL. Pharmacocinétique et tolérance de la ceftriaxone après injection sous-cutanée. [Pharmacokinetics and tolerance of ceftriaxone after subcutaneous administration] Pathol Biol (Paris) 1988;36(5 Pt 2):702–705.
    1. Harb G, Lebel F, Battikha J, Thackara JW. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin. 2010;26(2):279–288.
    1. Gauthier D, Schambach S, Crouzet J, Sirvain S, Fraisse T. Subcutaneous and intravenous ceftriaxone administration in patients more than 75 years of age. Med Mal Infect. 2014;44(6):275–280.
    1. Barbot A, Venisse N, Rayeh F, Bouquet S, Debaene B, Mimoz O. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med. 2003;29(9):1528–1534.
    1. Carpentier E, Roméo B, El Samad Y, Geslin-Lichtenberger L, Maingourd Y, Tourneux P. Subcutaneous teicoplanin for children with infectious endocarditis. Arch Ped. 2013;20(7):775–778.
    1. Leng B, Saux MC, Latrille J. Comparative pharmacokinetics of amikacin after intravenous, intramuscular and subcutaneous administration. Nouv Presse Med. 1979;8(42):3421–3425.
    1. Plantin P, Mahe M, Le Noac’h E, Le Roy JP. Cutaneous necroses after subcutaneous injections of amikacin. Presse Med. 1993;22(29):1366.
    1. Penso D, Delfraissy JF, Pham Van T, Dormont J. Skin necrosis following administration of subcutaneous gentamicin. Presse Med. 1984;13(25):1575–1576.
    1. Al-Omari A, Cameron DW, Lee C, Corrales-Medina VF. Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review. BMC Infect Dis. 2014;14:140.
    1. Lalani T, Chu VH, Park LP, Cecchi E, et al. In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis. JAMA Intern Med. 2013;173(16):1495–1504.
    1. Gaca JG, Sheng S, Daneshmand MA, et al. Outcomes for endocarditis surgery in North America: a simplified risk scoring system. J Thorac Cardiovasc Surg. 2011;141(1):98–106. e1–2.
    1. De Feo M, Cotrufo M, Carozza A, et al. The need for a specific risk prediction system in native valve infective endocarditis surgery. Scientific World Journal. 2012;2012:307571.
    1. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE) Eur J Cardio-Thorac Surg. 1999;16(1):9–13.
    1. Shahian DM, O’Brien SM, Filardo G, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1 – coronary artery bypass grafting surgery. Ann Thorac Surg. 2009;88(1 Suppl):S2–S22.
    1. Bernstein AD, Parsonnet V. Bedside estimation of risk as an aid for decision-making in cardiac surgery. Ann Thorac Surg. 2000;69(3):823–828.
    1. Afilalo J, Mottillo S, Eisenberg MJ, et al. Addition of frailty and disability to cardiac surgery risk scores identifies elderly patients at high risk of mortality or major morbidity. Circ Cardiovasc Qual Outcomes. 2012;5(2):222–228.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir